Rapid Fire
DengiAll
- 03 Jul 2025
- 2 min read
India’s efforts to develop a safe and effective dengue vaccine have taken a significant leap forward, with its first indigenous tetravalent dengue vaccine, DengiAll, reaching 50% enrolment in Phase 3 clinical trials.
- DengiAll: It is developed by Panacea Biotec under a licensing agreement with the US National Institutes of Health (NIH), targeting all four dengue virus subtypes.
- The vaccine has shown a balanced and robust immune response in Phase I and II trials, with no major safety concerns reported.
- The vaccine is significant as dengue currently has no specific treatment for everyone, and severe cases can lead to life-threatening complications like internal bleeding and shock.
- Dengue: It is a mosquito-borne viral disease caused by the dengue virus (genus Flavivirus), primarily transmitted by the female Aedes aegypti mosquito.
- This mosquito also spreads chikungunya, yellow fever, and Zika. There are four distinct but related dengue serotypes: DEN-1, DEN-2, DEN-3, and DEN-4.
- Symptoms: High fever, severe headache, eye pain, muscle and joint pain, rash, and fatigue.
- Diagnosis and Treatment: Diagnosis is done via blood test. There is no specific antiviral treatment; care is supportive.
- Dengvaxia is the first dengue vaccine approved by the US FDA in 2019; for ages 9–16 with prior infection in endemic regions.
- Burden: India continues to bear a heavy dengue burden over 2.3 lakh cases and 297 deaths in 2024, making vaccine development crucial.
| Read more: Dengue |
